Innate Immune Reprogramming Mediated by Endogenous Retroelement Dysregulation Drives Multiple Sclerosis Progression
Annals of Clinical and Translational Neurology · 2026-08 · 13 (8) · 1673-1685
DOI: 10.1002/acn3.70350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 23.02.2026. Verfasst von Li-Mei Xiao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Fujian Institute of Neurology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Multiple Sclerosis, Immunity, Innate, Myelopoiesis, COVID-19. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Skewed myelopoiesis in the bone marrow has been identified as a key driver of multiple sclerosis (MS) progression. Interestingly, SARS‐CoV‐2 infection, which has a severe impact on MS patients, can also induce similar skewed myelopoiesis. This shared phenotype raises the question of whether a common mechanism underlies the skewed myelopoiesis in both diseases. Previous studies in mice have demonstrated that the dysregulation of endogenous retroelements (EREs) in HSPCs leads to skewed myelopoiesis. Building on this, we sought to determine whether ERE dysregulation contributes to the skewed myelopoiesis observed in MS and after COVID‐19, which remains challenging.
Methods
We undertook a joint investigation of two public single‐cell/nuclei cohorts respectively representing MS and following COVID‐19. Both cohorts were processed through an identical bioinformatic pipeline to ensure comparable assessment of gene and ERE expression.
Results
We observed enhanced myelopoiesis in the bone marrow of MS patients compared to healthy controls, along with downregulation of the ERE repressor H3.3 and concomitant EREs overexpression. Notably, a similar epigenetic and transcript feature was found in post‐COVID‐19 individuals.
Conclusion
The H3.3 low /ERE high signature may not only explain the common skewed myelopoiesis in MS and post‐COVID‐19 conditions, but also provide a mechanistic link between infection and the innate immune reprogramming that drives MS progression. This offers a novel therapeutic insight for MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Fujian Institute of Neurology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
- Department of Neurology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
- Fujian Key Laboratory of Molecular Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, China.
ORCID-Profile: Wan-Jin Chen, Ying Fu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xiao, L. M., Zhao, Q. P., Li, R. Y., Chen, W., Song, H. H., Chen, W. J., & Fu, Y. (2026). Innate Immune Reprogramming Mediated by Endogenous Retroelement Dysregulation Drives Multiple Sclerosis Progression. Annals of Clinical and Translational Neurology, 13(8), 1673-1685. https://doi.org/10.1002/acn3.70350
Vancouver
Xiao LM, Zhao QP, Li RY, Chen W, Song HH, Chen WJ, et al. Innate Immune Reprogramming Mediated by Endogenous Retroelement Dysregulation Drives Multiple Sclerosis Progression. Annals of Clinical and Translational Neurology. 2026;13(8):1673-1685. doi:10.1002/acn3.70350
BibTeX
@article{Xiao2026,
author = {Xiao, Li-Mei and Zhao, Qiu-Ping and Li, Run-Yun and Chen, Wei and Song, Huan-Huan and Chen, Wan-Jin and Fu, Ying},
title = {Innate Immune Reprogramming Mediated by Endogenous Retroelement Dysregulation Drives Multiple Sclerosis Progression},
journal = {Annals of Clinical and Translational Neurology},
year = {2026},
volume = {13},
number = {8},
pages = {1673--1685},
doi = {10.1002/acn3.70350}
}
EUVIMED